TOG Review (RCOG Journal)
MRCOG Part 2
Sexual and Reproductive Health
Update on recurrent vulvovaginal candidiasis
Key Statistics
- ≥4/yr — Episodes defining RVVC
- 130 million — Women affected worldwide/yr
- 80–89% — RVVC due to c. albicans
Don't-miss facts
-
RVVC = ≥4 episodes/12 months, ≥2 confirmed by culture/microscopy (≥1 by culture)
-
C. albicans causes 80–89% of RVVC; C. glabrata is inherently azole-resistant – send species ID/sensitivities
-
Vaginal pH ≤4.5 → favours VVC; >4.5 → favours BV/TV
-
BASHH induction: fluconazole 150 mg PO every 72h ×3, then weekly ×6 months maintenance (or clotrimazole pessary equivalent)
-
Fluconazole suppression 93% effective but 80% relapse on stopping; 7.5% resistance develops
-
Avoid oral azoles in pregnancy – use topical clotrimazole; extended 7-day course gives 90% cure vs 50% at 4 days
-
Breastfeeding OK after single 150 mg fluconazole dose only; avoid repeat/high doses
-
Watch for hypokalaemia/QT prolongation with multi-dose azoles; topical treatments can damage condoms
Do not treat
Asymptomatic colonisation (up to 20% of women)
Abbreviation Key
- VVC — vulvovaginal candidiasis
- HbA1c — glycated haemoglobin
- RVVC — recurrent vulvovaginal candidiasis
- NAAT — nucleic acid amplification test
- BASHH — British Association for Sexual Health and HIV
- TV — Trichomonas vaginalis
- MBL — mannose binding lectin
- BV — bacterial vaginosis
Source: Borland A et al. Update on recurrent vulvovaginal candidiasis. The Obstetrician & Gynaecologist 2021;23:295–300. doi:10.1111/tog.12772
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).